Roche’s Oral SERD Giredestrant Delays Early Breast Cancer Recurrence in Late-Stage Trial
Roche; oral SERD; giredestrant; Phase 3 trial; early breast cancer; ER-positive; HER2-negative; disease-free survival; adjuvant therapy; recurrence prevention
Merck Continues Cuts: 204 Employees Laid Off in New Jersey
Merck; layoffs; New Jersey; Rahway; pharmaceutical; cost-cutting; restructuring; WARN notice; global workforce reduction; Keytruda; Gardasil; biopharma industry
Jazz and Zymeworks Bispecific Antibody Zanidatamab Delivers Practice-Changing Results in Stomach Cancer Study
Jazz Pharmaceuticals; Zymeworks; zanidatamab; bispecific antibody; HER2; gastroesophageal adenocarcinoma; stomach cancer; phase 2 trial; phase 3 HERIZON-GEA-01; overall survival; progression-free survival; chemotherapy; practice-changing; Orphan Drug designation
Genmab Discontinues ProfoundBio-Derived ADC GEN1107 After Acquisition, Paralleling J&J’s Ambrx Buyout Area Developments
Genmab; ProfoundBio; antibody-drug conjugate (ADC); GEN1107; PTK7; Ambrx; Johnson & Johnson (J&J); oncology; drug development; biotech acquisition; AbbVie lawsuit
Artios Pharma Raises $115 Million Series D to Advance DNA Damage Response Cancer Therapies
Artios Pharma; Series D financing; DNA Damage Response (DDR); cancer therapies; alnodesertib; ART6043; oncology pipeline; pancreatic cancer; colorectal cancer; breast cancer; investors; clinical trials
Solve Therapeutics Raises $120M to Advance Next-Generation ADCs for Solid Tumors
Solve Therapeutics; antibody-drug conjugates; ADC; CloakLink linker technology; solid tumors; oncology; SLV-154; SLV-324; clinical trials; venture capital; Yosemite; Merck
Eli Lilly to Acquire Adverum Biotechnologies in Gene Therapy Deal; Captain T Cell Secures €20M Funding
Eli Lilly; Adverum Biotechnologies; Acquisition; Gene therapy; Ixo-vec; Contingent Value Rights (CVR); Ophthalmology; Captain T Cell; Financing; Biotech investment
Terray Therapeutics Unveils EMMI: AI-Driven Platform Revolutionizes Small Molecule Drug Discovery
Terray Therapeutics; EMMI; generative AI; small molecule drug discovery; AI-native platform; chemical space; drug optimization; biotech; machine learning; COATI model
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)
Bright Minds Biosciences; Scientific Advisory Board; Prader-Willi Syndrome; PWS; BMB-101; BMB-105; clinical trials; neurodevelopmental disorders
NewcelX Appoints Jeremy Shefner to Scientific Advisory Board
NewcelX; Jeremy Shefner; Scientific Advisory Board; ALS; AstroRx; neurodegenerative disease; Barrow Neurological Institute; cell therapy; clinical trials